OCTO Acquires Nebula Systems, Reinforces Its Leadership in Intelligent Vehicle Diagnostics
4.12.2019 14:00:00 EET | Business Wire | Press release
OCTO Telematics, the leading global provider in transforming an IoT Big Data set into actionable intelligence, has acquired the entire share capital of Nebula Systems Ltd.
Nebula specialises in the development of advanced cloud technologies for the automotive and connected car industries. This means that its proprietary technologies are now available to make vehicle systems and data more accessible, so that a vehicle’s health, status and operation can be monitored, analysed, diagnosed and maintained, faster and more effectively than ever before - anytime and anywhere.
OCTO continues its investment strategy in companies with high technological value, pursuing continuous portfolio innovation and market leadership. The acquisition confirms OCTO’s unwavering commitment to respond to the increasing demand for vehicle usage data analysis tools, with advantages for insurance, automotive and mobility companies with its increasingly integrated and complete offering.
Modern cars are full of sensors that generate huge amounts of valuable data that can be used to enhance both the driver and fleet manager experience. The vast majority of this data is related to OEM Electronic Control Unit (ECU), protocol and CAN bus which are difficult for the aftermarket to access. The Nebula Systems diagnostic cloud solution is based on an integrated circuit and a suite of vehicle data analysis software applications in order to better respond to the increased complexity. An integrated circuit, developed with proprietary technology, grants deep access to OEM level data. Vehicle telematics can therefore benefit from combining this telematics chipset with proprietary analysis software, which gives OCTO the ultimate flexibility and ease of access to OEM vehicle data by using a unique VIN-specific configuration file that contains the instructions to read Parameter ID (PID) sets from any OEM ECU on virtually any car.
This technology uniquely combines the proprietary chipset and a cloud-based VIN interpreter and configuration files builder to fully access all the ECUs and thousands of PIDs a vehicle may have.
“We are very proud of this latest acquisition which places OCTO amongst the leading providers of fleet telematics leasing and renting organizations” says Nicola Veratelli, OCTO Group CEO. “Amongst many trends that are changing the mobility sector there are some that have a significant impact on fleet managers, such as the need to integrate data coming from the vehicle, each different from the other and defined for each manufacturer. OCTO solves the complexity of interpreting this data and offers impactful solutions which contribute to deliver additional value for fleet managers. We are committed to offer dozens of fleet telematics services to fleet managers and drivers: remote cloud-based diagnostics deriving from this Nebula acquisition is surely one of the most relevant.”
With this acquisition, the Nebula technology will be integrated in the standard OCTO offering. Furthermore, all OCTO telematics devices will integrate these capabilities, allowing OCTO solutions full access to all OEM ECUs and to use diagnostic trouble codes and Parameter IDs for the benefit of both drivers and fleet managers. The combination of these benefits will have a substantial impact on mobility management costs for fleet managers using the OCTO Fleet Telematics solution.
About OCTO
Founded in 2002, OCTO is today the Number 1 global provider of telematics and data analytics solutions for the auto insurance industry and, increasingly, a major player in Fleet management services, with world-class solutions to grow its core businesses – Insurtech and Intelligent Mobility – and to expand and provide innovative connected solutions in new industries and international markets.
OCTO’s vision is to connect the world of mobility through advanced analytics and IoT-driven services for a new era of Smart Telematics.
OCTO currently has 6 million connected users, holds the largest global database of telematics data, with more than 248 billion miles of driving data collected and over 464,000 crashes and insurance events analysed, and runs more than 10 car sharing services with more than 400,000 hires per month.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005088/en/
Contact information
OCTO Telematics
Adriana Zambon
press.it@octotelematics.com
m: +39 339.3995640
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom